VivoSeq
Other

Assisted Reproductive Technology

0

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Assisted Reproductive Technology is an early-stage landscape with 0 programs across 3 companies. The most active players are Merck & Co., Ferring, Luye Pharma Group Ltd..

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

0 programs

PreclinicalFerring logo

Ferring

0 programs

PreclinicalLuye Pharma Group Ltd. logo

Luye Pharma Group Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

17

clinical trials

Completed13 · 76%
Unknown status3 · 18%
Active, not recruiting1 · 6%

Clinical Trials

Trial Activity

17 trials

Identify Effective Doses of LY01021 in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)
Active, not recruiting·Luye Pharma Group Ltd. logoLuye Pharma Group Ltd.·Phase 2·NCT07236476·90 enrolled
CONSORT Randomized Controlled Trial in Assisted Reproductive Technology
Completed·Merck & Co. logoMerck & Co.·Phase 4·NCT00829244·200 enrolled
Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)
Completed·Merck & Co. logoMerck & Co.·Phase 2·NCT00505752·520 enrolled
Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT01185704·136 enrolled
Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT02047227·939 enrolled
Convenience and Safety of Assisted Reproductive Technology Procedures Using a Gonal-F Filled by Mass (Fbm) Liquid Formulation Applied by Pen for Ovulation Induction and In-vitro Fertilization
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT01183143·215 enrolled
Outcome of Two Protocols in Poor Responders in Assisted Reproductive Technology (ART) Cycle
Completed·RRoyan Institute·Phase 3·NCT01006954·200 enrolled
A Retrospective Study in Chinese Good Prognosis Patients Undergoing Assisted Reproductive Technology (ART) Treatment
Completed·Merck & Co. logoMerck & Co.·N/A·NCT02889380·3,000 enrolled
Identify Effective Doses of SHR7280 Tablets in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)
Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT05082233·85 enrolled
Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART)
Completed·Ferring logoFerring·Phase 3·NCT04163458·405 enrolled
Post-Authorisation Study on the Use of Bemfola® in Human Assisted Reproductive Technology
Completed·FFinox AG·N/A·NCT02942849·1,195 enrolled
Evaluation of Efficacy and Safety of Highly Purified Urofollitropin in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program
Completed·Ferring logoFerring·Phase 3·NCT01922193·263 enrolled
Clinical Safety Study of the Progesterone Vaginal Ring in Women Undergoing Assisted Reproductive Technology Procedures
Completed·Ferring logoFerring·Phase 3·NCT03565211·352 enrolled
Compare the Efficacy of Human Albumin With Cabergoline to Prevent Ovarian Hyper Stimulation in Assisted Reproductive Technology (ART) Program
Completed·RRoyan Institute·Phase 1/2·NCT01009567·10 enrolled
The Effect of Metformin on Fecundability in an ART(Assisted Reproductive Technology) Setting - the Correlation to Uterine Flows
Unknown status·TThe Baruch Padeh Medical Center, Poriya·Phase 2·NCT02848950·100 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)